Accessibility information | Access Keys
We are developing a Drug-Eluting Bead (CellBead Neuro) for the treatment of neurological trauma and neurological degeneration.
The cosmetic dermatology programme in partnership with the Merz Group is focused on the dermal filler market segment.
Glucagon Like Peptide is widely viewed as an important emerging treatment for diabetes and obesity.
A Haemoglobin test kit for testing the haemoglobin level in human blood which is primarily sold to blood banks and doctors' surgeries.
Biocompatibles International plc is a leading medical technology company in the field of drug device combination products, operating through two businesses. CellMed is developing a bead product for cosmetic dermatology and a Drug-Eluting Bead product for the treatment of stroke, based on proprietary stem cell technology. Biocompatibles UK supplies bead and Drug-Eluting Bead products, primarily for use in oncology, and supplies polymer for Medtronic's Endeavor® drug-eluting stent product. Our strategic partners include Angiodynamics Inc, Medtronic Inc, Merz AG and Terumo Corporation.
Drug-Eluting Beads Agreement with Eisai Co. Ltd - 16/05/2008
Proposed Dividend, based on Royalty Income - 15/05/2008
Interim Management Statement - 22/04/2008